Experimental and clinical psychopharmacology最新文献

{"title":"Acceptability and feasibility of a mobile health program for smoking cessation in low-resource populations.","authors":"Devin C Tomlinson, Erin E Bonar, Lauren Zimmermann, Anne Fernandez, Golfo Tzilos Wernette, Inbal Nahum-Shani, Lara N Coughlin","doi":"10.1037/pha0000833","DOIUrl":"10.1037/pha0000833","url":null,"abstract":"<p><p>Cigarette smoking is the leading cause of preventable death in the United States. We evaluate the feasibility and acceptability of a digital contingency management intervention for tobacco cessation among Medicaid beneficiaries with a pilot microrandomized trial. Participants (<i>N</i> = 37; 63.9% annual income <$15,000), self-enrolled across community-based health centers, were incentivized monetarily to submit breath samples twice daily for 4 weeks, with additional incentives for negative samples (≤6 parts per million carbon monoxide). Participants were randomized twice daily with fixed probability to be sent motivational messages or not manually through an app. We evaluate acceptability and feasibility of the program. Using a generalization of regression suitable for a binary outcome, we examine the average effect of delivering a message (vs. no message) on proximal sample submissions and smoking status. Thirty-three participants who completed a posttest assessment (97.1%) reported they would recommend the program to others. Participants submitted 69.5% of the expected samples (1,440 of 2,072 total) where 66.7% (960 of 1,440 total) of submissions were smoke negative. At the postintervention breath test, 61.3% (19 of 31 who submitted a breath sample) had a negative sample (i.e., 51.4% of all 37 participants). After adjusting for previous sample submission, participants were 7% more likely (risk ratio 1.07; 95% confidence interval [1.01, 1.14]) to submit a sample after a motivational message was delivered (vs. not delivered). The results support the incorporation of motivational messages into research involving contingency management for tobacco cessation. (PsycInfo Database Record (c) 2026 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":" ","pages":"277-288"},"PeriodicalIF":1.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146212694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A behavioral economics substance-free activity session (SFAS) approach to reducing substance use: Narrative review and intervention manual.","authors":"James G Murphy, Hannah E Cole, Ashley A Dennhardt, Avery C Buck, William J Davis, Aglaia M Margaris, Jacob Tempchin, Ebonie T White, Meghan E McDevitt-Murphy, Brian Borsari","doi":"10.1037/pha0000831","DOIUrl":"10.1037/pha0000831","url":null,"abstract":"<p><p>Standard brief alcohol and drug use interventions focus on motivating reductions in use and associated harms and have shown reliable reductions in these outcomes. However, effect sizes are small, and dissemination is limited by low rates of help seeking. Incorporating intervention elements focused on enhancing wellness, mood, and goal pursuit might enhance efficacy and appeal. The substance-free activity session (SFAS) integrates behavioral economic and motivational interviewing elements to enhance goal-directed and mood-enhancing activity patterns that might provide alternatives to alcohol- and drug-related reward. We conducted a narrative review of 15 empirical studies that investigated the efficacy of the SFAS and evaluated mechanisms of behavior change. We then provide an overview of how to conduct the SFAS, including a session vignette. There is support for the efficacy of the SFAS when integrated with standard brief alcohol interventions for college students. There is also evidence that the SFAS reduces negative affective symptoms and increases self-regulation and proportionate reinforcement from substance-free activities. Evidence for cannabis use reductions is less robust. The SFAS has been successfully implemented as an adjunct to intensive alcohol and drug treatment for adults, but not in the context of adequately powered efficacy trials. The clinical vignette and intervention manual provides a model for how to motivate an individual to pursue reductions in substance use supported by increased engagement in goal-directed and enjoyable substance-free activities. The SFAS shows promise as a brief intervention that supports substance use reductions via motivating patterns of substance-free activities. (PsycInfo Database Record (c) 2026 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":" ","pages":"305-317"},"PeriodicalIF":1.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12970588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147364550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of vaped cannabis on the severity of naloxone-precipitated opioid withdrawal.","authors":"Jermaine D Jones, Suky Martinez, Caroline Arout, Margaret Haney, Felipe Castillo, Jeanne Manubay, Freymon Perez, Rachel R Luba, Sandra D Comer","doi":"10.1037/pha0000796","DOIUrl":"10.1037/pha0000796","url":null,"abstract":"<p><p>Naloxone administration can precipitate opioid withdrawal, concerns about which may result in hesitancy to use this life-saving intervention. Preclinical and clinical research suggests that cannabinoids may reduce the symptoms associated with opioid withdrawal. This proof-of-concept study sought to test the effects of vaporized cannabis pretreatment (T^-15 min) on naloxone-precipitated (T0-T⁺50) withdrawal using the Clinical Opiate Withdrawal Scale (COWS, range = 0-48) as the primary dependent measure. Evaluating the safety of this drug combination was the secondary aim, assessed using vital signs. Before a major methodological redesign, a single participant (male, 52) with opioid use disorder completed testing. The ∼4-week inpatient study began with stabilization on oral morphine (120 mg/day). During testing, the following dose combinations of vaped cannabis (V-CB) and intranasal naloxone (IN-NLX) were tested: (a) IN-NLX 0.0 mg + V-CB 25.0 mg, (b) IN-NLX 4.0 mg + V-CB 0.0 mg, (c) IN-NLX 0.0 mg + V-CB 12.5 mg, (d) IN-NLX 4.0 mg + V-CB 12.5 mg, (e) IN-NLX 0.0 mg + V-CB 0.0 mg, and (f) IN-NLX 4.0 mg + V-CB 25.0 mg. Naloxone alone resulted in a COWS score of 22 at T+30. CB pretreatment (12.5 mg and 25.0 mg) reduced COWS scores at T+30 to 17 and 14, respectively. Active NLX and V-CB administered in combination resulted in elevated heart rate and blood pressure, though not to a greater extent than NLX alone. This study found that the addition of a cannabinoid reduced the severity of NLX-precipitated withdrawal and supported the continued investigation into combined NLX + cannabinoid formulations as overdose reversal agents. (PsycInfo Database Record (c) 2026 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":" ","pages":"318-323"},"PeriodicalIF":1.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12590582/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144948098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regulatory science methods can test the addictive properties of foods: A proof-of-concept pilot study.","authors":"Tera L Fazzino, Matthew S Stratton, Matthew Lange, Ashley N Gearhardt, Jennifer W Tidey","doi":"10.1037/pha0000818","DOIUrl":"10.1037/pha0000818","url":null,"abstract":"<p><p>Hyper-palatable foods (HPF) contain pairs of ingredients (e.g., fat and sodium) at thresholds not found in nature. The ingredient pairs in hyper-palatable foods are hypothesized to drive their reinforcing properties; however, this premise has not been tested using abuse liability assessment methodology. This proof-of-concept pilot used an acute dose-effects paradigm to evaluate the reinforcing effects of full-dose hyper-palatable foods (potato chips) versus negative control and modified-dose stimuli. This within-subjects, double-blind, crossover-design study was conducted with <i>N</i> = 20 participants in a laboratory setting. Food stimuli consisted of regular potato chips; a negative control low in fat, sodium, and carbohydrates (Jicama vegetable chip, baked); and modified-dose potato chips (either no fat or no sodium). In each of four sessions, participants completed an acute subjective effects test, a food purchase task to evaluate demand elasticity for each chip condition (sensitivity to escalating prices), and a self-administration task, which characterized break point, the highest level at which participants worked to self-administer chips with escalating response requirements. Full-dose chips were rated significantly higher on liking, wanting, craving, and willingness to eat again, versus negative control (<i>p</i> = .011-.0001). Participants exhibited lower demand elasticity for the full-dose chips (<i>p</i> < .0001), and higher break point (<i>p</i> < .0001), suggesting they valued full-dose chips more as reinforcers versus negative control. A similar pattern was observed for the modified-dose chips versus negative control, with smaller differences. Findings overall indicated dose-response effects across the stimuli, supporting the premise that abuse liability assessment methodology can be applied to test the addictive properties of hyper-palatable foods. (PsycInfo Database Record (c) 2026 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":" ","pages":"295-304"},"PeriodicalIF":1.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147813008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"How do I reduce the fear of missing out?\" analyzing Reddit discussion of how people deal with the fear of missing out when reducing their alcohol use.","authors":"Kendell Dew, Megan Cook, Taylor Winter, Benjamin Riordan","doi":"10.1037/pha0000816","DOIUrl":"10.1037/pha0000816","url":null,"abstract":"<p><p>Alcohol use remains a public health concern due to the harm it can have on both the drinker and those around the drinker. One emerging factor that could be targeted by interventions is the fear of missing out (FoMO). FoMO is the sense that others are having rewarding experiences that you are missing out on, and research has found a link between FoMO and both alcohol use and harm. The aim of this study was to identify and describe how people who are aiming to reduce their drinking overcome or deal with FoMO to inform future intervention content. To address this aim, we collected and analyzed the content of 2,476 posts on Reddit about FoMO and alcohol use. Suggestions identified to reduce FoMO included reframing FoMO to focus on the positives of disconnecting from alcohol, focusing on other nonalcohol-related activities, finding friends who do not drink, and attending events sober. Results provide a foundation for future research into interventions that target FoMO, with the possibility for future research to expand upon these data to develop an evidence-based harm-reduction method. (PsycInfo Database Record (c) 2026 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":" ","pages":"289-294"},"PeriodicalIF":1.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145773977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glitches to growth: Lessons learned from developing and testing an augmented reality smartphone app for substance use treatment.","authors":"Marilyn Horta, Ranjita Poudel, Karen O Brandon, Skye O Dougan, Helen Yates, Madison S Rivera, Ursula Martinez, Steven K Sutton, Damon J Vidrine, Lee M Ritterband, Kara P Wiseman, Katrina A Vickerman, Kea Turner, Margaret M Byrne, Min-Jeong Yang, Oyedolapo A Anyanwu, Thomas H Brandon, Christine Vinci","doi":"10.1037/pha0000815","DOIUrl":"10.1037/pha0000815","url":null,"abstract":"<p><p>Augmented reality (AR) is an advanced technology that has emerged as a helpful tool in mobile health interventions for substance use treatment. By superimposing virtual drug-related cues in one's real-world environment, AR could expand the delivery of extinction-based cue exposure therapies while mitigating costs and risks. Previous findings from our team show AR smoking cues elicit cravings like in vivo cues, with evidence of extinction after repeated AR exposure trials. Based on these findings, we developed an AR smoking cessation smartphone app to test as an adjuvant to a state tobacco quitline in an ongoing large-scale randomized controlled trial (NCT06088498). This article describes AR technology and its theoretical relevance to cue exposure therapies, as well as challenges related to app development, trial enrollment, and app engagement. Although some challenges and recommendations unique to AR are discussed (e.g., development of smoking-related AR images), most are relevant to the broader application of other advanced mobile health technologies. Examples include finding and collaborating with industry partners, such as app developers, with sufficient expertise in the relevant technology and in research; potential for selection bias based on smartphone capabilities and participants' technological abilities and affinities; explaining the novel treatment rationale within the app; and maximizing app engagement. Where relevant, these points will be illustrated with data collected during the randomized controlled trial. Recommendations offered may have utility for investigators and clinicians interested in AR and other advanced technologies (e.g., virtual reality, geo-mapping, wearables) to improve the reach and efficacy of treatments for substance use disorders. (PsycInfo Database Record (c) 2026 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":" ","pages":"261-270"},"PeriodicalIF":1.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12716370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145773993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective effect of concurrent bupropion and citicoline treatment on lipopolysaccharide-induced depression- and anxiety-like behavior in mice: The role of neuroinflammation.","authors":"Seyyedeh Elaheh Mousavi, Zeinab Afrand Khalilabad, Moein Ghasemi, Ali Lesani, Seyedeh Sahar Alemohammad, Amirabbas Mohammadi Hamaneh","doi":"10.1037/pha0000845","DOIUrl":"10.1037/pha0000845","url":null,"abstract":"<p><p>Depression and anxiety cause substantial functional disabilities, and current treatments often have limited efficacy and notable adverse effects. Developing adjunctive therapies may help address these shortcomings. With established neuroprotective and antidepressant properties, citicoline may improve outcomes and minimize adverse effects. To assess citicoline as an adjuvant to bupropion in a lipopolysaccharide-induced model of depression and anxiety. Six-week-old male Naval Medical Research Institute mice were assigned to control or experimental groups receiving lipopolysaccharide alone or followed by daily bupropion (60 or 100 mg/kg), citicoline (25 or 75 mg/kg), or their combination. On Day 14, behavioral evaluations were performed in 8-week-old mice using the elevated plus maze, open field test, and forced swimming test, and hippocampal tumor necrosis factor-alpha, interleukin-1beta, malondialdehyde, and nitric oxide levels were assessed. Coadministration of low-dose bupropion (60 mg/kg) with an otherwise ineffective dose of citicoline (25 mg/kg) significantly improved anxiety- and depression-like behaviors in the elevated plus maze and forced swimming test and reduced hippocampal tumor necrosis factor-alpha, interleukin-1beta, malondialdehyde, and nitric oxide metabolites. These effects were consistently greater than those of bupropion (60 mg/kg) alone and were comparable or even superior to those achieved with the higher bupropion dose (100 mg/kg). Citicoline appears to positively potentiate bupropion's efficacy against depression- and anxiety-like behaviors in preclinical models of these human disorders, at least in part through attenuation of neuroinflammatory and oxidative processes. These findings suggest a promising experimental strategy that may help guide future clinical studies, particularly for unresponsive individuals. (PsycInfo Database Record (c) 2026 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":" ","pages":"196-206"},"PeriodicalIF":1.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147498013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Behavioral pharmacology study to inform the switching potential and abuse liability of tobacco-flavored and menthol-flavored pod-based electronic nicotine delivery systems with 5% nicotine concentration.","authors":"Nicholas I Goldenson, Saul Shiffman, Mark A Sembower, Ryan A Black","doi":"10.1037/pha0000848","DOIUrl":"10.1037/pha0000848","url":null,"abstract":"<p><p>To benefit public health, electronic nicotine delivery systems (ENDS) must be sufficiently satisfying to adults who smoke to promote switching away from cigarettes while presenting limited risk of persistent use and dependence among nonusers of tobacco products. This behavioral pharmacology study evaluated the abuse liability and switching potential of four pod-based ENDS (tobacco and menthol flavors) relative to cigarettes. U.S. adults who smoked cigarettes daily (N = 78; 51.3% female; Mage[SD] = 42.91 [9.84]; 53.8% non-Hispanic White; mean cigarettes/day [SD] = 14.42 [11.96]) completed a randomized five-arm crossover behavioral pharmacology study. On 5 separate days, participants used one of four pod-based ENDS, all with 5.0% nicotine concentrations (JUUL2 Virginia Tobacco, NJOY Ace Classic Tobacco, JUUL2 Fresh Menthol, JUUL Menthol 5.0%), or smoked their usual brand cigarette for 20 min ad libitum. After using each product, questionnaires assessed subjective reinforcing and sensory effects relevant to abuse liability and potential for switching away from cigarettes. All ENDS products were rated statistically significantly and meaningfully lower than usual brand cigarette on subjective reinforcing effects (ps < .001; Cohen's ds = 0.58-1.73). The tobacco- and menthol-flavored ENDS were generally rated similarly on measures of subjective reinforcing and sensory effects, but JUUL2 Fresh Menthol 5% was rated significantly higher than the other ENDS on the modified Product Evaluation Scale satisfaction subscale (ps ≤ .01; Cohen's ds = 0.38-0.59). The abuse liability of all tobacco- and menthol-flavored pod-based ENDS in this study is likely substantially lower than cigarettes. The results regarding subjective satisfaction suggest that the switching potential of JUUL2 Fresh Menthol 5% may be higher than tobacco-flavored ENDS. (PsycInfo Database Record (c) 2026 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":"34 2","pages":"153-162"},"PeriodicalIF":1.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147698007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of digital cognitive-behavioral therapy for insomnia in heavy drinkers with insomnia: A replication and extension study.","authors":"Justin J Verlinden, Mairead E Moloney, Olga A Vsevolozhskaya, Lee M Ritterband, Karen S Ingersoll, Avrie Barthel, Jessica Weafer","doi":"10.1037/pha0000834","DOIUrl":"10.1037/pha0000834","url":null,"abstract":"<p><p>Poor sleep and problematic drinking share a bidirectional relationship. Recent studies have targeted sleep as a novel means of improving drinking outcomes, including a prior pilot trial by our group which showed that a digital insomnia intervention (Sleep Healthy Using the Internet [SHUTi]) significantly improved sleep and drinking outcomes to a greater degree than a patient education (PE) program. In the present study, we aimed to replicate and extend our prior findings by assessing diary-derived measures of sleep and alcohol use as well as mental health outcomes in a larger sample. One hundred thirteen heavy drinkers with insomnia were randomly assigned to either the SHUTi (<i>n</i> = 61) or a sleep PE program (<i>n</i> = 52). Participants completed assessments immediately following the intervention period (9 weeks) and again at 3- and 6-months postintervention. Linear mixed-effects models showed that those in the SHUTi condition reported significantly greater improvements in sleep and greater reductions in drinking frequency relative to the PE condition. Additionally, those in the SHUTi condition reported greater reductions in depression symptoms and sleep medication use relative to the PE condition. Limitations include relatively high attrition, reliance on self-report measures, and demographic homogeneity. These findings replicate and extend the pilot trial results and support the utility of incorporating sleep interventions into alcohol use disorder prevention and treatment efforts. (PsycInfo Database Record (c) 2026 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":" ","pages":"175-188"},"PeriodicalIF":1.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12970601/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147364561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are dating and sexual Protective Behavioral Strategies (PBS) associated with alcohol-related consequences at all levels of alcohol use?","authors":"Roselyn Peterson, Sthefani C Paitan, Olivia A Belitsos, Joliza C Maynard, Jennifer E Merrill, Robert Dvorak","doi":"10.1037/pha0000838","DOIUrl":"10.1037/pha0000838","url":null,"abstract":"<p><p>Alcohol use is common among college students and often linked to negative consequences. Protective behavioral strategies (PBS) can reduce alcohol use and related harms. This study examined whether dating/sexual PBS provide unique protective effects beyond alcohol PBS. We tested three hypotheses: (1) dating/sexual PBS would predict fewer drinks at follow up, controlling for alcohol PBS; (2) dating/sexual PBS would predict fewer alcohol-related consequences at follow up, controlling for alcohol PBS; and (3) drinks per week would moderate the association between dating/sexual PBS and consequences, with stronger protection for heavier drinkers. Participants (<i>n</i> = 324; 78.1% female, <i>M</i>_age = 19.2, <i>SD</i> = 2.2, 71.3% White) completed baseline and 1-month follow-up surveys measuring alcohol PBS, dating/sexual PBS, typical drinks per week, and alcohol-related consequences. Baseline dating/sexual PBS did not predict follow-up drinks per week after controlling for alcohol PBS, logistic regression χ²(7) = 100.59, Cragg-Uhler <i>R</i>² = .281. However, dating/sexual PBS predicted fewer follow-up alcohol-related consequences (incident rate ratios [IRR] = 0.73, <i>p</i> = .022), with drinks per week moderating this effect. Contrary to expectation, dating/sexual PBS were protective at low levels of drinking (IRR = 0.57, <i>p</i> = .002) but not at high levels (IRR = 0.88, <i>p</i> = .391). Dating/sexual PBS reduce alcohol-related consequences over 1-month, particularly among students with low to average drinking levels. These findings emphasize the importance of both alcohol-specific and dating/sexual PBS in college alcohol risk reduction interventions. (PsycInfo Database Record (c) 2026 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":" ","pages":"189-195"},"PeriodicalIF":1.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147389993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}